title: Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia.
abstract: BACKGROUND
  Genome variability of host genome and cancer cells play critical role in diversity of response to existing therapies and overall success in treating oncological diseases. In chronic myeloid leukemia targeted therapy with tyrosine kinase inhibitors demonstrates high efficacy in most of the patients. However about 15 % of patients demonstrate primary resistance to standard therapy. Whole exome sequencing is a good tool for unbiased search of genetic variations important for prognosis of survival and therapy efficacy in many cancers. We apply this approach to CML patients with optimal response and failure of tyrosine kinase therapy.
  
  
  RESULTS
  We analyzed exome variations between optimal responders and failures and found 7 variants in cancer-related genes with different genotypes in two groups of patients. Five of them were found in optimal responders: rs11579366, rs1990236, rs176037, rs10653661, rs3803264 and two in failures: rs3099950, rs9471966. These variants were found in genes associated with cancers (ANKRD35, DNAH9, MAGEC1, TOX3) or participating in cancer-related signaling pathways (THSD1, MORN2, PTCRA).
  
  
  CONCLUSIONS
  We found gene variants which may become early predictors of the therapy outcome and allow development of new early prognostic tests for estimation of therapy efficacy in CML patients. Normal genetic variation may influence therapy efficacy during targeted treatment of cancers.
authors.affiliation: Laboratory of Mutagenesis, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, 115478, Russia. alexandervlavrov@gmail.com.|Department of Molecular and Cellular Genetics, State Budgetary Educational Institution of Higher Professional Education "Russian National Research Medical University named after N.I. Pirogov" of Ministry of Health of the Russian Federation, Moscow, Russia. alexandervlavrov@gmail.com.
authors.forename: Alexander V
authors.initials: AV
authors.lastname: Lavrov
authors.affiliation: Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.
authors.forename: Ekaterina Y
authors.initials: EY
authors.lastname: Chelysheva
authors.affiliation: Laboratory of Mutagenesis, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, 115478, Russia.
authors.forename: Svetlana A
authors.initials: SA
authors.lastname: Smirnikhina
authors.affiliation: Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.
authors.forename: Oleg A
authors.initials: OA
authors.lastname: Shukhov
authors.affiliation: Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.
authors.forename: Anna G
authors.initials: AG
authors.lastname: Turkina
authors.affiliation: Laboratory of Mutagenesis, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, 115478, Russia.
authors.forename: Elmira P
authors.initials: EP
authors.lastname: Adilgereeva
authors.affiliation: Laboratory of Mutagenesis, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, 115478, Russia.|Department of Molecular and Cellular Genetics, State Budgetary Educational Institution of Higher Professional Education "Russian National Research Medical University named after N.I. Pirogov" of Ministry of Health of the Russian Federation, Moscow, Russia.
authors.forename: Sergey I
authors.initials: SI
authors.lastname: Kutsev
mesh_terms: D000328:Adult; D059472:Exome; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D008297:Male; D009363:Neoplasm Proteins / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis
chemical_list: D009363:Neoplasm Proteins
references.citation: Mol Cell. 2000 Jul;6(1):11-22
references.pmid: 10949023
references.citation: Mod Pathol. 2012 Jun;25(6):828-37
references.pmid: 22411186
references.citation: BMC Bioinformatics. 2009 Feb 03;10:48
references.pmid: 19192299
references.citation: Oncotarget. 2014 Oct 30;5(20):10198-205
references.pmid: 25415353
references.citation: Nat Immunol. 2013 Jun;14(6):619-32
references.pmid: 23644507
references.citation: Cancer Control. 2009 Apr;16(2):122-31
references.pmid: 19337198
references.citation: Mol Genet Genomic Med. 2013 Nov;1(4):246-59
references.pmid: 24498620
references.citation: Cancer Sci. 2014 Jan;105(1):105-9
references.pmid: 24450386
references.citation: BMC Cancer. 2015 Jan 30;15:22
references.pmid: 25632947
references.citation: Blood. 2000 Nov 15;96(10):3343-56
references.pmid: 11071626
references.citation: Oncol Rep. 2014 Jul;32(1):159-66
references.pmid: 24842123
references.citation: Int J Oncol. 2012 Aug;41(2):490-6
references.pmid: 22664866
references.citation: Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2568-78
references.pmid: 25139936
references.citation: Mol Biol Rep. 2014 Jun;41(6):3715-22
references.pmid: 24532140
references.citation: Am J Manag Care. 2012 Nov;18(11 Suppl):S257-64
references.pmid: 23327457
references.citation: Cancer Immunol Res. 2014 May;2(5):480-6
references.pmid: 24795360
references.citation: Nucleic Acids Res. 2015 Jan;43(2):760-74
references.pmid: 25539926
references.citation: Haematologica. 2010 May;95(5):785-93
references.pmid: 20015885
references.citation: Nucleic Acids Res. 2010 Sep;38(16):e164
references.pmid: 20601685
references.citation: Blood. 2006 Jun 1;107(11):4317-25
references.pmid: 16455951
references.citation: Blood. 2013 Aug 8;122(6):872-84
references.pmid: 23803709
references.citation: Blood. 2006 Nov 15;108(10):3484-93
references.pmid: 16857994
references.citation: Leukemia. 2011 Jan;25(1):7-22
references.pmid: 21102425
references.citation: Mol Cell Proteomics. 2005 Dec;4(12):1898-909
references.pmid: 16147992
references.citation: Genome Res. 2001 May;11(5):863-74
references.pmid: 11337480
references.citation: Am J Hum Genet. 2007 Feb;80(2):232-40
references.pmid: 17236129
references.citation: Bioinformatics. 2010 Aug 15;26(16):2069-70
references.pmid: 20562413
references.citation: Cancer Immunol Immunother. 2013 Jan;62(1):191-5
references.pmid: 23180015
references.citation: J Clin Oncol. 2011 Oct 10;29(29):3944-5
references.pmid: 21900102
references.citation: Nat Methods. 2010 Apr;7(4):248-9
references.pmid: 20354512
references.citation: Nat Biotechnol. 2011 Jan;29(1):24-6
references.pmid: 21221095
references.citation: Cell Host Microbe. 2014 Sep 10;16(3):338-50
references.pmid: 25211076
references.citation: J Huazhong Univ Sci Technolog Med Sci. 2014 Apr;34(2):181-185
references.pmid: 24710929
references.citation: Brief Bioinform. 2013 Mar;14(2):178-92
references.pmid: 22517427
references.citation: PLoS One. 2015 Mar 30;10(3):e0122502
references.pmid: 25822849